ScoreWhy is Senores Pharmaceuticals Ltd ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.94 times
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.94 times
- The company has been able to generate a Return on Capital Employed (avg) of 8.61% signifying low profitability per unit of total capital (equity and debt)
2
Healthy long term growth as Net Sales has grown by an annual rate of 85.60% and Operating profit at 130.72%
3
With a growth in Net Profit of 138.15%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- NET SALES(Q) Highest at Rs 161.76 cr
- OPERATING PROFIT TO INTEREST(Q) Highest at 8.00 times
- PAT(Q) Highest at Rs 32.38 cr.
4
With ROE of 7.2, it has a Very Expensive valuation with a 4.4 Price to Book Value
- Over the past year, while the stock has generated a return of 0.00%, its profits have risen by 86%
5
Majority shareholders : Promoters
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Senores Pharma. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
71.70%
EBIT Growth (5y)
108.34%
EBIT to Interest (avg)
4.69
Debt to EBITDA (avg)
3.61
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.42
Tax Ratio
23.62%
Dividend Payout Ratio
0
Pledged Shares
1.90%
Institutional Holding
13.25%
ROCE (avg)
9.51%
ROE (avg)
9.90%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
51
Industry P/E
34
Price to Book Value
6.26
EV to EBIT
40.12
EV to EBITDA
33.22
EV to Capital Employed
5.40
EV to Sales
9.34
PEG Ratio
0.52
Dividend Yield
NA
ROCE (Latest)
13.47%
ROE (Latest)
12.36%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Bullish
Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
PAT(Latest six months)
At Rs 63.27 cr has Grown at 80.72%
NET SALES(Q)
Highest at Rs 175.19 cr
-9What is not working for the Company
INTEREST(Q)
Highest at Rs 8.46 cr
NON-OPERATING INCOME(Q)
is 37.28 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Senores Pharma.
Profit After Tax (PAT) - Latest six months
At Rs 63.27 cr has Grown at 80.72%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 175.19 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Here's what is not working for Senores Pharma.
Interest - Quarterly
At Rs 8.46 cr has Grown at 58.72%
Quarter on Quarter (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Interest - Quarterly
Highest at Rs 8.46 cr
in the last five quarters and Increased by 58.72 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Non Operating Income - Quarterly
is 37.28 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
Non Operating Income - Quarterly
Highest at Rs 17.67 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
